PHBI Stock Overview
Operates as a nutraceutical company, engages in the formulating products from blends of therapeutic plants and fungi in North America. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Pharmagreen Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0018 |
| 52 Week High | US$0.0047 |
| 52 Week Low | US$0.0005 |
| Beta | 2.08 |
| 11 Month Change | -11.76% |
| 3 Month Change | 80.00% |
| 1 Year Change | 176.92% |
| 33 Year Change | -91.78% |
| 5 Year Change | -99.75% |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHBI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.3% | 2.8% | 1.0% |
| 1Y | 176.9% | 13.3% | 31.4% |
Return vs Industry: PHBI exceeded the US Pharmaceuticals industry which returned 13.1% over the past year.
Return vs Market: PHBI exceeded the US Market which returned 30.7% over the past year.
Price Volatility
| PHBI volatility | |
|---|---|
| PHBI Average Weekly Movement | 30.3% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PHBI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PHBI's weekly volatility (30%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Peter Wojcik | www.pharmagreen.ca |
Pharmagreen Biotech Inc. operates as a nutraceutical company, engages in the formulating products from blends of therapeutic plants and fungi in North America. Its primary product is MaxGenomic supplement, a proprietary blend and formulated medicinal mushrooms and medical plants to support the human mind and body. The company also provides consulting services for plant genetic selection, tissue culture technologies for starter plantlets production, SOPs for cultivation and live storage of any plant species services.
Pharmagreen Biotech Inc. Fundamentals Summary
| PHBI fundamental statistics | |
|---|---|
| Market cap | US$1.19m |
| Earnings (TTM) | -US$403.84k |
| Revenue (TTM) | US$4.35k |
274.8x
P/S Ratio-3.0x
P/E RatioIs PHBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHBI income statement (TTM) | |
|---|---|
| Revenue | US$4.35k |
| Cost of Revenue | US$1.99k |
| Gross Profit | US$2.35k |
| Other Expenses | US$406.20k |
| Earnings | -US$403.84k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00061 |
| Gross Margin | 54.15% |
| Net Profit Margin | -9,290.13% |
| Debt/Equity Ratio | -15.2% |
How did PHBI perform over the long term?
See historical performance and comparison